Why the study?
Do platelet glycoprotein IIb/IIIa antagonists improve outcomes in patients with coronary artery disease?
Do platelet glycoprotein IIb/IIIa antagonists improve outcomes in patients with coronary artery disease?
This review provides an overview of clinical trials investigating glycoprotein IIb/IIIa antagonists for the treatment of coronary artery disease.
Answers are grounded in this paper and cite their sources.
Synthesizes GP IIb/IIIa antagonist trials in CAD; leaves open their role in contemporary practice.
There is a growing understanding of the central role that platelets play in coronary artery disease. The glycoprotein IIb/IIIa receptor has recently been identified as the final common pathway for platelet aggregation and hence has been the focus of many clinical trials to influence various aspects of coronary artery disease. In this report we give an overview of these clinical trials.
No takes yet. Share an insight, caveat, or question.
Salam et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: